Tausch E, et al. - Since genomic aberrations, IGHV mutation status and mutations in genes such as TP53 are established prognostic factors in CLL in the context of chemoimmunotherapy, researchers analyzed their role when using chemo-free regimens such as obinutuzumab (GA-101) plus venetoclax (Ven-G). In the phase 3 CLL14 trial comparing G-Clb vs Ven-G in patients with CIRS>6 or creatinine clearance < 70 ml/min, they evaluated the incidence and impact of genomic aberrations via FISH, mutations in 13 genes via NGS and IGHV status. There were 107 events for progression-free survival (PFS) and 37 for overall survival (OS) in the intention to treat population at a median follow-up of 29 months. According to findings, the prognostic value of genomic aberrations, IGHV and gene mutations were confirmed for G-Clb, whereas with Ven-G only del(17p) and TP53^mut were linked to short PFS and only del(17p) with short OS. IGHV^unmut has been recognized as a predictive variable identifying a group of patients benefiting from Ven-G in specific.